HER2 inhibitors are primarily used to treat HER2-positive breast cancer, which accounts for about 20% of all breast cancer cases. They are also used in the treatment of HER2-positive gastric and gastroesophageal junction cancers, and their potential use in other HER2-overexpressing cancers is currently being explored in clinical trials.
